RxDoctor Payments Data

Curtis Steyers, MD

Clinical Cardiac Electrophysiology · Saint Louis, MONPI 1861745721

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (35.2%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Abbott at 32.8% of the total. Reporting peaked in 2019 at $8,060 and has fallen 69.4% since, to $2,468 in 2025.

$22,466in general payments, 2019–2025

Across 322 payments — averaging $69.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Boston Scientific$6K
  • Biosense Webster, Inc.$3K
  • Medical Device Business Services, Inc.$3K
  • Atricure, Inc.$2K
  • Medtronic$509
  • plus $676 from 13 others

What the payments were for

  • Consulting fees$2,25010%
  • Grants$5,00022%
  • Travel & lodging$7,29732%
  • Food & beverage$7,91935%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,466 in reported general payments places this provider in the 60th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

See all clinical cardiac electrophysiology providers in Missouri

Medicare billing

Part B allowed, 2024
$337,303
Medicare patients
702
Services billed
3,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban564$545,670
XareltoRivaroxaban165$154,053
Flecainide Acetate177$9,185
Metoprolol Succinate401$5,463
Amiodarone Hcl166$3,174
SotalolSotalol Hcl174$2,535
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$1,896
Diltiazem 24hr Er (Xr)Diltiazem Hcl55$1,337
Metoprolol Tartrate222$1,319
Dilt-XrDiltiazem Hcl40$1,051
Pantoprazole Sodium106$570
Carvedilol59$489
Cephalexin75$301
Dabigatran EtexilateDabigatran Etexilate Mesylate13$190
Atenolol15$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$545,670564 claims
Johnson & JohnsonXarelto$59$154,053165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

Other clinical cardiac electrophysiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →